ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Effects of Additional Chinese Herbal Medicines Treatment in Patients with Type 2 Diabetes Mellitus Combined with Stable Angina Pectoris: A Retrospective Cohort Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chinese herbal medicines (CHMs) are used for type 2 diabetes mellitus combined with stable angina pectoris (T2DM-SAP), but their long-term effects lack real-world evidence. Objective: To evaluate the effects of additional CHMs on angina readmission rates compared to standard treatment alone in patients with T2DM-SAP. Methods: This retrospective cohort study included 704 patients with T2DM-SAP. Participants were stratified into two groups based on cumulative CHMs use (≥ 3 months). The CHMs group included 115 patients, while the non-CHMs group included 589 patients. A 1:1 propensity score matching (PSM) was used to balance differences between groups. The primary outcome was angina readmission. The secondary outcomes were SAP readmission and unstable angina pectoris (UA) readmission. Kaplan-Meier survival curves were plotted before and after matching. Sensitivity analysis was performed using Cox proportional hazards model. Baseline prescriptions were collected and herbal frequency and efficacy were counted. Results: After matching, there were 106 patients in each of the two groups. Before matching, compared with the non-CHMs group, the adjusted hazard ratio (aHR) of angina readmission in the CHMs group was 0.49 [95% confidence interval (CI): 0.34, 0.71, Conclusion: Additional CHMs treatment can significantly reduce the incidence of angina readmission and prolongs the interval to recurrent events in T2DM-SAP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.